bedast

As noted in the article, it bans the app from the app stores, not individual devices. It doesn't penalize individuals for having and using the app.

I have my own domain attached to icloud mail at the moment. But primarily, I have my own domain and can move it to wherever I need it. Icloud mail isn't the best thing in the world, still, but it's more cost efficient than trying to run it on a personal O365 or some other service for now. I don't really have need for the enhanced security/privacy of some of the other providers available, at least for now, but having my own domain means migrating to them later, should I need it, shouldn't be difficult.

I will note the icloud mail web interface is utter garbage.

I'm frequently reminding people that Google is not an email provider nor a search engine nor really anything else it pretends to be, but that it's a data harvesting and ad company.

Thankfully I've been becoming less reliant on my gmail inbox. But also, it appears my various efforts for blocking malicious content may be blocking these ads because I don't see them on my home network.

Sometimes it's not just about getting rid of an annoyance. I've stuck to my guns with ad blocking to protect myself from malicious ad content. In terms of content creators getting paid, I pay for a Youtube Premium subscription to help with that (which, it's my understanding content creators get paid MORE by Youtube Premium views than ad supported views).

Reading the article, I failed to see what link they found. The headline here matches the one on the article so I'm not calling that into question, but what seems to be more accurate is "Mobile phone calls correlated with increased risk of high blood pressure" since no actual causal link is established. The article repeatedly calls it out as a link as well. It'd be easy for certain groups to fill in the blanks and claim this proves mobile radiation is a health risk, while it doesn't at all establish that causal link. Just as easily, it could be inferred that longer calls are more stressful. And also just as easily the link could be established that those with a family history of hypertension or have other risk factors are more likely to have longer phone conversations.

So I'd argue there's no established link, but there might be an obvious correlation that might warrant more study.

In my experience, the White Ambiance lights don't get as dim as the other Hue bulbs. In places where I wanted even lower light, I've had to use their White Ambiance Filament or Color Ambiance bulbs.

I've noticed the White Ambiance lights don't dim to a very low level for night time night light type of use, but the White and Color Ambiance bulbs can get far dimmer. Also the White Ambiance Filament bulbs seem to get dimmer than the regular White Ambiance bulbs.

It's a shame, really, because it seems like the expensive bulbs might meet your needs while their cheaper ones don't. Granted, the filament bulbs do seem to fall more in line with the regular bulbs, so might be worth exploring.

I have a box of batteries I need to dispose of that I haven't just tossed in the garbage.

My local Home Depot used to take batteries, but only non-lithium ion batteries. And sometime last year they stopped accepting any batteries.

I still haven't found a local place that I can easily access to get rid of these things. And I'm tired of keeping them around.

I feel like there's not enough easily accessible information in the wild about what you're supposed to do with old electronics, and especially batteries. You're not supposed to throw any type of battery in the trash, let alone ones that get really angry when abused. And places that used to take old batteries seem to be refusing them now. I have a small box of old batteries I've been looking to dispose of and I'm running out of places to try and give them to.

It especially doesn't help that electronics, including with non-replaceable batteries, including those that get angry when abused, are being designed to be disposable to begin with.

And yeah, I know there's a high level of apathy about the problem with the masses. Even though the information can be, for the most part, found, people just don't care enough.

The article notes that, yes, he will remain as spokesperson.

You might get a good few years from the drug. You have to still do the work to make the changes permanent.

In my experience, if you're going to use GLP-1 RA for weight loss, it needs to be part of a larger program of changes, including lifestyle changes. That you have to lead the charge on. The people that say losing weight on these means you gotta take it for the rest of your life, they're wrong. It eventually stops having that effect on you. It certainly makes the process of changing things a lot easier, and it buys you a lot of time to adopt those changes. But if you don't put in the mental work and reshape your lifestyle to this new body, you're going to have a bad time later regardless of if you're still on it or not.

I've taken various GLP-1 RA over a decade for glycemic management (I'm on Mounjaro now). They still work great for this. But I have to do the work to maintain my body, now.

Mounjaro will never be approved for obesity. The documentation for dosing is for diabetes. If the trend follows with how Novo Nordisk has released their versions of this, dosing for weight loss will be different than dosing for diabetes care, and so it must be under a whole new label.

Mounjaro is a trade name for a diabetes drug and that won't change. So no, it is not soundly rejected.

It's not as simple as "SQUIRT JUICE INSIDE ME GET THINNER AND CURE DIABETES". There's a lot more to this than you seem to understand.

This is not only an American issue. I've seen people in the UK struggle to get access to treatments and devices through the NHS. Canada tends to follow what the US is doing even though they have their more socialized system. It all tends to be a bit of a mess with brand new drugs and devices. And Mounjaro is new as of last year (approval less than a year ago?).

Do you even know what A1c is? Or how GLP-1 RA achieves this goal?

GLP-1 RA does NOT achieve a reduced A1c through weight loss. It achieves improved glycemic control by slowing the release of glucose into the blood as well as promoting increased production of insulin in response to glucose. The overall result is a reduction in blood glucose.

A1c is a measure of your glycemic health that spans around 90 days with heavier weight on more recent trends. It's like a longer blood glucose average measurement. There are actually algorithms that can calculate an estimate of your A1c based on blood glucose trends, which is referred to GMI (glucose management indicator).

The gastric effects leading to feeling full sooner and longer are a side effect and is what leads to weight loss. It also fades with time. Having been on various GLP-1 RAs over a decade, they don't provide this benefit to me anymore. Even with Mounjaro also being a GIP, it's just doing its primary job for me.

Tirzepatide is in testing. The weight loss variant will not be called Mounjaro. If they follow similar patterns from Novo Nordisk with Saxenda and Wegovy, dosing will be different for the weight loss variant, which means it won't carry the same label.

You are among the people just learning about this class of drug. It's been around since 2004 (Byetta). I've been taking it since 2012 (Victoza). Even then, it was known to promote weight loss (Saxenda approved around 2014).

This is not a new hotness. And many diabetics have used this drug class for a long time.

And yeah, you're jumping into conspiracy theory. Ramping up production would likely take significant investment. Do they have the resources? Probably. But given the weight loss benefit is temporary (seriously, it is, ask anyone who has used one of these drugs for a significant amount of time), do you think they're going to sink significant investment into production when demand is going to wane in a few years? Well, you see, their investors are going to say no, and they hold the final say.

Significantly increasing production for a temporary benefit is going to require significant investment. Since it is a temporary benefit, it's probably not worth that significant investment. Because eventually the demand will falter.

And yeah, the weight loss benefit is a temporary benefit. It may last a few years, but it fades. This is not a new drug class. The weight loss aspect to it is also not new (Saxenda, the weight loss variant of Victoza, released in 2014). Liraglutide was in trials for weight management when I started Victoza. That was a decade ago. I'm on Mounjaro now for glycemic management and it works great for that. But it's not doing anything for appetite, delayed gastric emptying, etc.

They also probably don't want to put significant investment in boosting production knowing that will be temporary since the weight loss effects aren't permanent. As someone who has been on GLP-1 RA for a decade, starting with Victoza, and now on Mounjaro, those weight loss benefits have no effect on me anymore. Delayed gastric emptying and appetite suppression is so far reduced that it might as well not be a thing anymore. But I don't use this drug for weight loss, I take it for glycemic management, and it still works great for that. I have to do the work to continue my weight loss and maintenance.

Yeah, these drugs aren't new but the wide world is just learning about the weight loss aspect. So they don't know this is a temporary solution.

Brand new drugs tend to take a while to get on insurance formularies. I believe Mounjaro is still missing in most formularies. Lilly wants people on their drug, not the competition.

Allowing the coupon to be used for the treatment of obesity is an implicit approval for the drug to be used in this way, and coupons are a form of marketing. Lilly cannot approve nor market this drug in a way that is off-label. This is why when Lilly talks about testing tirzepatide for weight loss, they say tirzepatide and not Mounjaro. Whenever you see articles mentioning Mounjaro for weight loss, these are statements not originating from Lilly.

That it is currently labeled only for Type 2 diabetes is a marketing decision by the manufacturer, not a characteristic of the drug.

Regulatory approval. It is a diabetes drug because it has been evaluated as such, including understanding the primary effects and side effects at various dosing levels. Mounjaro is prescribed to diabetics from 2.5mg to 15mg in increments of 2.5mg and titrated based on needs and goals.

Typically, weight loss versions of these drugs (Saxenda and Wegovy) are dosed higher than their diabetes counterpart, and are just titrated to maximum dose over time to maximize weight loss benefits. So evaluation is based on this, and approval follows this.

Various drugs do get used for off-label purposes, but the drug makers can't promote this because their marketing claims are regulated. This is why the coupon terms were changed.

I care that many people I know are losing glycemic control because they're going on a waiting list for their medication while Kim K and Elon Musk and TikTok promote easy mode cosmetic weight loss.

And dose. The doses are different. You need a much higher dose than is typically prescribed for diabetes to get the full weight loss benefits.

Part of getting approval for on-label use of these drugs is understanding this part of it.

Yes, this is what Novo Nordisk did with Victoza around 2014 with the release of Saxenda. And then again with Ozempic around 2021 with Wegovy. These weight loss versions exist. And there will be one likely this year based on tirzepatide from Lilly (I haven't looked up if they have a name for it yet).

It's weird for anyone to "feel abandoned by Big Pharma" when you abused a coupon to get a drug for off-label use, and terms were changed to match its on-label use. Especially when there's versions of these drugs with on-label use for weight loss.

Yeah, feel free to spend the $1200/mo for it then. Because that's off-label use when there are drugs in this class with on-label weight loss use. And sometime this year, tirzepatide is expected to be among them.

The coupon was changed because people were abusing it. This drug is approved for diabetes, not weight loss.

The biggest problem using these drugs for weight loss is they need to be used as part of a program that also includes making lifestyle changes. If you don't push the changes and just do things to your limits, when you stop the drug, your unchanged habits make you gain the weight back.

This is one of the biggest things people with obesity struggle with. This is seen as a miracle cure for obesity because it doesn't require work, just a weekly injection and watch the weight melt off. But making lifestyle changes (changing eating habits, increasing activity, etc) is the most reliable way to make this a permanent fix.

But that's putting the patient to work and they don't want that.

If she has insurance and a diabetes diagnosis, the coupon should apply. The coupon is still there. I use it.

Mounjaro is not an obesity drug. It's a type 2 diabetes drug. Do not call it an obesity drug.

The headline is editorialized. The linked article's headline: The ‘next Ozempic’ became a social media sensation. Then everything changed

The coupon didn't go away. The coupon's terms changed. I'm using the coupon now. Because I have type 2 diabetes. The coupon changed because people were using it to get the drug for off-label use. The drug wasn't taken away from people trying to lose weight by jacking up the cost. The drug shouldn't have been dispensed in this way to begin with.

Lilly is seeking to get approval of tirzepatide under a different label as a weight loss drug, similar to how Ozempic and Wegovy exist, as well as Victoza and Saxenda.

If you want a GLP-1 RA (this drug class) for weight loss, go get Wegovy or Saxenda, which are a version of these drugs approved for weight loss for those with a BMI over 30, or wait for the tirzepatide version. Leave the diabetes drugs alone.

And to be clear: This drug isn't helping diabetics by helping them lose weight. It helps diabetics regulate blood glucose. It slows the release of glucose from the liver as well as promotes the release of insulin from the pancreas. Weight loss due to slowed stomach emptying is a side effect.